CA125 and Placental Alkaline Phosphatase as Serum Tumor Markers in Epithelial Ovarian Carcinoma

Authors:
  • VÁVera M. ÁBeler
    Vera M. ÁBeler
  • OBOle P. BØRmer
    Ole P. BØRmer
  • TSTorgny Stigbrand
    Torgny Stigbrand
  • CTClaes Trope
    Claes Trope
  • KNKjell Nustad
    Kjell Nustad

Abstract
Placental alkaline phosphatase (PLAP) was measured by an immunoradiometric assay using the monoclonal antibody C2 (PLAP-C2). Serum samples of 135 patients with epithelial ovarian cancer were analyzed, and the results were compared with CA125 levels. CA125 and PLAP-C2 were elevated in 85 and 43% of the patients, respectively. Only 1 patient with normal CA125 and evidence of disease at the time of sampling had an elevated PLAP-C2. Fifty-three patients with measurable tumor were followed longitudinally during chemotherapy. Correct correlation with disease evolution was observed in 95% of the patients for CA125 and in 59% for PLAP-C2. The PLAP-C2 assay did not add significantly to the predictive value of CA125 in the diagnosis and follow-up of epithelial ovarian cancer.